China Universal Asset Management Co., Ltd.
Position in LYEL — Lyell Immunopharma, Inc.
CIK 1906594
SHANGHAI, F4
Position in LYEL
as of Mar 31, 2026
· filed Apr 28, 2026
Position Value
$75,626
-$30,780 QoQ
Shares Held
3,770
+9.1% QoQ
Ownership
0.016%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026China Universal Asset Management Co., Ltd. holds $172,298,843 across 225 Biotechnology names. LYEL ranks #173 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
43,902 | $19,603,999 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
21,361 | $16,504,363 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
27,266 | $9,021,501 | |
| 4 | INSM |
INSMED Inc
|
47,015 | $7,687,892 | |
| 5 | RPRX |
Royalty Pharma plc
|
130,447 | $6,257,542 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
77,315 | $5,805,583 | |
| 7 | ARGX |
Argenx SE
|
5,035 | $3,676,808 | |
| 8 | MRNA |
Moderna, Inc.
|
70,085 | $3,560,318 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $75,626 | 3,770 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $106,406 | 3,457 | Shares | Sole | 2026-01-29 | |
| 2025-09-30 | $54,680 | 3,367 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $26,219 | 2,966 | Shares | Sole | 2025-08-28 | |
| No filing history on record for this holder in this stock. | ||||||